Summary
The primary purpose of this study for Part 1 (Dose Escalation) is to identify the safe, effective dose (recommended Phase 2 doses [RP2Ds]) and dosing schedule for a new drug called JNJ-79635322 treatment regimen in combination with either daratumumab or pomalidomide; and Part 2 (Dose Expansion) is to further define the safety and tolerability of JNJ-79635322 combination treatment regimens at selected RP2D(s).
Eligible participants will be assigned to one of two treatment arms, depending on whether they have had prior treatment or not.
In the Experimental Treatment Regimen A arm, participants will receive JNJ-79635322 + Daratumumab targeted therapy.
Participants who have received 1-3 prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulating drug (Treatment regimen A1) will receive a dose of JNJ-79635322 subcutaneously along with daratumumab (both given subcutaneously, which means as injections under the skin) to establish the RP2Ds of the JNJ-79635322 during Part 1 of the study.
Based on the study evaluation team (SET) decision, enrollment may proceed in participants with newly diagnosed multiple myeloma (NDMM) (Treatment Regimen A2). Dose escalation and de-escalation will be based on SET evaluation. In Part 2 (Dose expansion) participants will receive a dose of JNJ-79635322 combination treatmen regimen(s) at the RP2D(s) determined in Part 1 and in disease subgroup(s) to determine the safety and tolerability of the combination treatment regimens.
In the Experimental Treatment Regimen B arm, participants will receive JNJ-79635322 + pomalidomide targeted therapy.
Participants who have received great than or equal to (>=)1 prior line of therapy, including a PI and lenalidomide, and are lenalidomide refractory or >=2 prior lines of therapy, including a PI and lenalidomide will receive a dose of JNJ-79635322 along with pomalidomide to establish the RP2D(s) of the JNJ-79635322 during Part 1 of the study.
Dose escalation and de-escalation will be based on SET evaluation.
In Part 2, participants will receive a dose of JNJ-79635322 combination treatment regimen(s) at the RP2D(s) determined in Part and in disease subgroup(s) to determine the safety and tolerability of the combination treatment regimens.